Ticker Details
CorMedix Inc. Cormedix Inc is a commercial-stage biopharmaceutical company. It focuses on development and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases.
IPO Date:	May 13, 2010
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$655.86M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.16 | 4.48%
Avg Daily Range (30 D):	$0.19 | 2.38%
Avg Daily Range (90 D):	$0.17 | 2.34%

Institutional Daily Volume
Avg Daily Volume:	.67M
Avg Daily Volume (30 D):	1.11M
Avg Daily Volume (90 D):	1.24M

Trade Size
Avg Trade Size (Sh.):	198
Avg Trade Size (Sh.) (30 D):	90
Avg Trade Size (Sh.) (90 D):	93

Institutional Trades
Total Institutional Trades:	998
Avg Institutional Trade:	$1.43M
Avg Institutional Trade (30 D):	$.93M
Avg Institutional Trade (90 D):	$1.15M
Avg Institutional Trade Volume:	.14M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$1.7M
Avg Closing Trade (30 D):	$.97M
Avg Closing Trade (90 D):	$1.1M
Avg Closing Volume:	181.12K

News

Dec 24, 2025 @ 8:42 AM CorMedix Builds a Real Revenue Story as DefenCath ... Source: Nathan Reiff

Nov 21, 2025 @ 2:00 PM American Kidney Fund Hosts Third Patient Access In... Source: Lavarne A. Burton

Nov 12, 2025 @ 4:00 PM Strong Earnings and Biotech Resilience Define the ... Source: Na

Sep 29, 2025 @ 12:30 PM CorMedix Announces Completion of Enrollment in Pha... Source: Globe Newswire

Sep 2, 2025 @ 11:30 AM CorMedix Completes Acquisition of Melinta Therapeu... Source: Globe Newswire

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$2.32	$.48	$.13
Diluted EPS	$2.04	$.43	$.07
Revenue	$400.05M	$127.43M	$128.62M
Gross Profit	$343.39M	$105.12M	$107.31M
Net Income / Loss	$181.01M	$38.6M	$14.02M
Operating Income / Loss	$193.67M	$63.66M	$59.13M
Cost of Revenue	$32.6M	$12.01M	$11.17M
Net Cash Flow	$112.68M	$33.25M	$96.34M
PE Ratio

Splits
Mar 26, 2019	1:5